Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
tumor
Staying alive: Can an experimental OMRF drug stop Mike Schuster’s brain cancer?
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
OMRF researchers identify genes that may cause cancer to recur after treatment
Cancer often returns after successful therapy, but why?
Military academy students get hands-on lab experience at OMRF
The Saxon program provides military academy students with an opportunity to work alongside OMRF senior scientists.
OMRF scientists identify protein that could drive colon cancer process
Research team’s new findings recently published in Nature Communications.
When cell division goes wrong
Get the sequence wrong and cell division can turn to disaster.
